The FDA has approved Corstasis Therapeutics’ Enbumyst (bumetanide nasal spray), the first self-administered nasal diuretic for the treatment of edema associated with congestive heart failure and hepatic and renal disease, including nephrotic syndrome in adults, according to a recent news release . It is expected to be available in the United States in the fourth quarter of 2025.

Enbumyst is the spray formulation of bumetanide, available as an oral tablet or injections for intravenous or intramuscular administration. Bumetanide was originally approved in 1983.

Enbumyst will utilize Aptar Pharma’s Unidose System , which is already used in more than 30 FDA- and EMA-approved therapies.

“We are pleased to see our Unidose System continually supporting innovative therapies that expand acce

See Full Page